Literature DB >> 28671665

Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease.

Zhentao Zhang1,2, Seong Su Kang2, Xia Liu2, Eun Hee Ahn2, Zhaohui Zhang1, Li He3, P Michael Iuvone3,4, Duc M Duong5,6, Nicholas T Seyfried5,6, Matthew J Benskey7, Fredric P Manfredsson7, Lingjing Jin8, Yi E Sun8, Jian-Zhi Wang9, Keqiang Ye2.   

Abstract

Aggregated forms of α-synuclein play a crucial role in the pathogenesis of synucleinopathies such as Parkinson's disease (PD). However, the molecular mechanisms underlying the pathogenic effects of α-synuclein are not completely understood. Here we show that asparagine endopeptidase (AEP) cleaves human α-synuclein, triggers its aggregation and escalates its neurotoxicity, thus leading to dopaminergic neuronal loss and motor impairments in a mouse model. AEP is activated and cleaves human α-synuclein at N103 in an age-dependent manner. AEP is highly activated in human brains with PD, and it fragments α-synuclein, which is found aggregated in Lewy bodies. Overexpression of the AEP-cleaved α-synuclein1-103 fragment in the substantia nigra induces both dopaminergic neuronal loss and movement defects in mice. In contrast, inhibition of AEP-mediated cleavage of α-synuclein (wild type and A53T mutant) diminishes α-synuclein's pathologic effects. Together, these findings support AEP's role as a key mediator of α-synuclein-related etiopathological effects in PD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28671665      PMCID: PMC5871868          DOI: 10.1038/nsmb.3433

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  45 in total

1.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

Authors:  Wolfgang Hoyer; Dmitry Cherny; Vinod Subramaniam; Thomas M Jovin
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

Review 4.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

5.  Age-related changes in brain energetics and phospholipid metabolism.

Authors:  Brent P Forester; Yosef A Berlow; David G Harper; J Eric Jensen; Nicholas Lange; Michael P Froimowitz; Caitlin Ravichandran; Dan V Iosifescu; Scott E Lukas; Perry F Renshaw; Bruce M Cohen
Journal:  NMR Biomed       Date:  2010-04       Impact factor: 4.044

6.  Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo.

Authors:  Dongtao Ni Li; Stephen P Matthews; Antony N Antoniou; Daniela Mazzeo; Colin Watts
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

7.  Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.

Authors:  Li Chen; Magali Periquet; Xu Wang; Alessandro Negro; Pamela J McLean; Bradley T Hyman; Mel B Feany
Journal:  J Clin Invest       Date:  2009-10-12       Impact factor: 14.808

8.  Dopamine modulates diurnal and circadian rhythms of protein phosphorylation in photoreceptor cells of mouse retina.

Authors:  Nikita Pozdeyev; Gianluca Tosini; Li Li; Fatima Ali; Stanislav Rozov; Rehwa H Lee; P Michael Iuvone
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

Review 9.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

10.  Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase.

Authors:  Zhixue Liu; Sung-Wuk Jang; Xia Liu; Dongmei Cheng; Junmin Peng; Manuel Yepes; Xiao-jiang Li; Steve Matthews; Colin Watts; Masahide Asano; Ikuko Hara-Nishimura; Hongbo R Luo; Keqiang Ye
Journal:  Mol Cell       Date:  2008-03-28       Impact factor: 17.970

View more
  63 in total

1.  Fluorescence spectroscopy reveals N-terminal order in fibrillar forms of α-synuclein.

Authors:  Conor M Haney; E James Petersson
Journal:  Chem Commun (Camb)       Date:  2018-01-18       Impact factor: 6.222

2.  Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer's disease.

Authors:  Hualong Wang; Xia Liu; Shengdi Chen; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

3.  Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson's Disease.

Authors:  Shilin Luo; Seong Su Kang; Zhi-Hao Wang; Xia Liu; Julia X Day; Zhiping Wu; Junmin Peng; Daxiong Xiang; Wolfdieter Springer; Keqiang Ye
Journal:  J Neurosci       Date:  2019-07-29       Impact factor: 6.167

4.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

5.  BDNF inhibits neurodegenerative disease-associated asparaginyl endopeptidase activity via phosphorylation by AKT.

Authors:  Zhi-Hao Wang; Wanqiang Wu; Seong Su Kang; Xia Liu; Zhiping Wu; Junmin Peng; Shan Ping Yu; Fredric P Manfredsson; Ivette M Sandoval; Xuebo Liu; Jian-Zhi Wang; Keqiang Ye
Journal:  JCI Insight       Date:  2018-08-23

6.  Structural Insights into α-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations.

Authors:  Xiaodan Ni; Ryan P McGlinchey; Jiansen Jiang; Jennifer C Lee
Journal:  J Mol Biol       Date:  2019-07-08       Impact factor: 5.469

Review 7.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

8.  The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease.

Authors:  Chun Chen; Zhihao Wang; Zhentao Zhang; Xia Liu; Seong Su Kang; Ying Zhang; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-02       Impact factor: 11.205

9.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

10.  Legumain Knockout Protects Against Aβ1-42-Induced AD-like Cognitive Deficits and Synaptic Plasticity Dysfunction Via Inhibiting Neuroinflammation Without Cleaving APP.

Authors:  Runwen Chen; Qiyue Zhang; Yuxing Yan; Yuying Zhang; Tao Zhang
Journal:  Mol Neurobiol       Date:  2020-11-21       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.